Who
Khoso Baluch
Director
Company insider
Files Form 4 as: Director, Processa Pharmaceuticals; Director, Longeveron; Chief Executive Officer, CorMedix.
In numbers
- Trades disclosed
- 48
- Buys
- 13
- Sells
- 1
- Bought
- $223K
- Sold
- $2,588
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 3 Oct 2016
- Last trade
- 26 Jul 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jul 2026filed 28 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,500 at $0.00 | filing |
| 26 Jul 2026filed 28 Jul 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,500 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —203 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —203 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —203 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —203 | filing |
| 31 Mar 2026filed 1 Apr 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,7522,269 at $2.54 | filing |
| 31 Mar 2026filed 1 Apr 2026 | PCSA Processa PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,7632,269 at $2.54 | filing |
| 1 Oct 2025filed 3 Oct 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | LGVN Longeveronoption or derivative · Biotechnology | SEC FORM 4 Code P | —29,415 | filing |
| 11 Aug 2025filed 13 Aug 2025 | LGVN LongeveronBiotechnology | SEC FORM 4 Bought | —11,766 | filing |
| 24 Jul 2025filed 28 Jul 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,299 at $0.00 | filing |
| 15 Jul 2025filed 17 Jul 2025 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | LGVN LongeveronBiotechnology | SEC FORM 4 Sold | $2,5881,250 at $2.07 | filing |
| 3 Sep 2024filed 18 Sep 2025 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,206 at $0.00 | filing |
| 3 Sep 2024filed 18 Sep 2024 | PCSA Processa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,206 at $0.00 | filing |
| 15 Aug 2024filed 19 Aug 2024 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 9 Jun 2024filed 11 Jun 2024 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $133125 at $1.06 | filing |
| 29 Dec 2023filed 2 Jan 2024 | LGVN LongeveronBiotechnology | SEC FORM 4 Bought | $12K8,322 at $1.43 | filing |
News
No headline names them, or the companies they trade most, lately.